Results 151 to 160 of about 16,540 (179)

Role of dipeptidyl peptidase IV (DPP4) in the development of dyslipidemia: DPP4 contributes to the steroid metabolism pathway

Life Sciences, 2011
We previously reported that dipeptidyl peptidase IV (DPP4)-deficient rats were susceptible to dyslipidemia induced by streptozotocin (STZ). Hence, it is suggested that DPP4 is important for lipid metabolism.In this study, to verify the role of DPP4 in the development of dyslipidemia, we carried out a microarray analysis of the livers of STZ-treated ...
Youichi Sato, Kazuo Minakuchi, Yutaka Nakahori   +2 more
exaly   +3 more sources

DPP4 inhibitors for diabetes—What next?

Biochemical Pharmacology, 2008
With vildagliptin and sitagliptin on the market for the treatment of type 2 diabetes, dipeptidyl peptidase 4 (DPP4, EC 3.4.14.5) research has entered a new era. Scientists aim to uncover the broader pharmacological profile of DPP4 inhibitors and search for therapeutic opportunities outside diabetes.
Lambeir, Anne-Marie, Scharpe, Simon, De Meester, Ingrid   +2 more
openaire   +3 more sources

Is DPP4 activity increased in PCOS?

Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2018
Dipeptidyl peptidase-4 (DPP4) is an adipokine with greater expression in visceral fat and related with insulin resistance (IR). Polycystic ovary syndrome (PCOS) is also associated with IR. Our study aims to evaluate DPP4 activity in PCOS.Thirty PCOS patients were compared to 28 healthy women.
Letícia Dinis da C, Braga, Amelio F, Godoy-Matos, Priscila de Oliveira, Siciliano, José Otávio do Amaral, Corrêa, Denise Pires, Carvalho   +4 more
openaire   +2 more sources

DPP4 Inhibitors: a new approach in diabetes treatment

Advances in Therapy, 2008
The role of dipeptidyl peptidase-IV (DPP4) as both a regulatory enzyme and a signalling factor has been evaluated and described in many studies. DPP4 inhibition results in increased blood concentration of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP).
John, Doupis, Aristidis, Veves
openaire   +2 more sources

Synthesis, SAR, and atropisomerism of imidazolopyrimidine DPP4 inhibitors

Bioorganic & Medicinal Chemistry Letters, 2010
The synthesis and SAR of aminomethyl-substituted imidazolopyrimidine DPP4 inhibitors bearing varied pendant aryl groups is described. Compound 1, which exists as a separable mixture of non-interconvertible atropisomers was used as the starting point for investigation.
Stephen P, O'Connor, Ying, Wang, Ligaya M, Simpkins, Robert P, Brigance, Wei, Meng, Aiying, Wang, Mark S, Kirby, Carolyn A, Weigelt, Lawrence G, Hamann   +8 more
openaire   +2 more sources

DPP4 Joins Weight Watchers

Science Translational Medicine, 2011
In patients with metabolic syndrome, human visceral fat secretes an adipokine DPP4 that impairs insulin signaling in muscle, potentially contributing to insulin resistance.
openaire   +1 more source

Pharmacological DPP4 inhibition for the prevention of vascular diseases

International Journal of Cardiology, 2016
Yang et al. have broadly summarized potential DPP4-dependentmolecular mechanisms for the development of atherosclerosis [1]. In our hands, vascular protective effects based on pharmacological inhibition of DPP4 can be seen in acute vascular injury as well as during initiation of atherosclerosis [2,3].
C, Brenner, W M, Franz
openaire   +2 more sources

Soluble DPP4 promotes hepatocyte lipid accumulation via SOX2-SCD1 signaling and counteracts DPP4 inhibition

Biochemical and Biophysical Research Communications
Dipeptidyl peptidase-4 (DPP4), a well-known target of antidiabetic therapy, is implicated in steatotic liver disease. However, its role in hepatic lipid metabolism, particularly the distinct functions of soluble DPP4 (sDPP4) and membrane-bound DPP4 (mbDPP4), remains unclear.
Chen Shen, Ha Ram Oh, Young Ran Park, Shinyoung Oh, Ji Hyun Park   +4 more
openaire   +2 more sources

Incretin effect: GLP-1, GIP, DPP4

Diabetes Research and Clinical Practice, 2011
The term incretin effect was used to describe the fact that oral glucose load produces a greater insulin response than that of an isoglycemic intravenous glucose infusion. This difference has been attributed to gastrointestinal peptides GLP-1 and GIP. Since incretin effect is reduced in subjects with type 2 diabetes, despite GLP-1 activity preservation,
openaire   +2 more sources

Bullous pemphigoid and DPP4 inhibitors

Medicina Clínica (English Edition), 2019
Rubén, García Castro, Elena, Godoy Gijón, Ana María, González Pérez, Concepción, Román Curto   +3 more
openaire   +2 more sources